| Consensus Statement on the Classification of Tremors. From the Task Force on Tremor of the International Parkinson and Movement Disorder Society |
133 |
| Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review |
109 |
| International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease |
79 |
| Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations |
55 |
| Update of the MDS research criteria for prodromal Parkinson's disease |
53 |
| Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and alpha-synuclein mechanisms |
51 |
| The Nasal and Gut Microbiome in Parkinson's Disease and Idiopathic Rapid Eye Movement Sleep Behavior Disorder |
51 |
| A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies |
48 |
| Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic |
36 |
| Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism |
34 |
| Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end? |
32 |
| Evaluation of Smartphone-Based Testing to Generate Exploratory Outcome Measures in a Phase 1 Parkinson's Disease Clinical Trial |
31 |
| Validation of the MDS clinical diagnostic criteria for Parkinson's disease |
30 |
| Treatment of Autonomic Dysfunction in Parkinson Disease and Other Synucleinopathies |
28 |
| Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK DJ1: MDSGene Systematic Review |
27 |
| EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease |
27 |
| Neuropathology of Autonomic Dysfunction in Synucleinopathies |
26 |
| Medical and Surgical Management of Advanced Parkinson's Disease |
26 |
| Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa) |
26 |
| Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054 |
26 |
| Treatment of Restless Legs Syndrome: Evidence-Based Review and Implications for Clinical Practice (Revised 2017) |
25 |
| Phosphorylated alpha-Synuclein in the Retina Is a Biomarker of Parkinson's Disease Pathology Severity |
24 |
| Fatigue in Parkinson's disease: A systematic review and meta-analysis |
23 |
| alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies |
23 |
| Pedunculopontine Nucleus Deep Brain Stimulation in Parkinson's Disease: A Clinical Review |
23 |
| Prodromal Parkinson's Disease: The Decade Past, the Decade to Come |
23 |
| The Tau Positron-Emission Tomography Tracer AV-1451 Binds With Similar Affinities to Tau Fibrils and Monoamine Oxidases |
22 |
| Speech treatment in Parkinson's disease: Randomized controlled trial (RCT) |
21 |
| Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson's disease |
21 |
| Cerebrospinal Fluid, Plasma, and Saliva in the BioFIND Study: Relationships Among Biomarkers and Parkinson's Disease Features |
21 |
| Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease |
21 |
| Directional Local Field Potentials: A Tool to Optimize Deep Brain Stimulation |
21 |
| Autonomic Dysfunction in Parkinson's Disease: A Prospective Cohort Study |
20 |
| Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort |
20 |
| Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy |
20 |
| Spinal Cord Stimulation Therapy for Gait Dysfunction in Advanced Parkinson's Disease Patients |
19 |
| SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson's disease |
19 |
| Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade |
19 |
| Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK VPS35: MDSGene systematic review |
19 |
| Four-year follow-up results of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor |
19 |
| Low-Fat Versus Ketogenic Diet in Parkinson's Disease: A Pilot Randomized Controlled Trial |
18 |
| Iron as a therapeutic target for Parkinson's disease |
18 |
| Facial emotion recognition in Parkinson's disease: A review and new hypotheses |
18 |
| Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease |
18 |
| Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy |
18 |
| How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy |
18 |
| Deep Brain Stimulation in Movement Disorders: From Experimental Surgery to Evidence-Based Therapy |
18 |
| Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease |
17 |
| Clinical and methodological challenges for assessing freezing of gait: Future perspectives |
17 |
| The Cerebral Basis of Parkinsonian Tremor: A Network Perspective |
17 |
